Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Bullous pemphigoid (BP) is a well-known condition triggered by autoantibodies directed against hemidesmosomal proteins involved in the adhesion of basal keratinocytes to the basement membrane.